Boehringer Ingelheim
- Business Wire
Aragen Announces Expansion of Discovery Research Agreement with Boehringer Ingelheim
HYDERABAD, India–(BUSINESS WIRE)–#Aragen–Aragen Life Sciences (formerly GVK BIO), a leading Contract Research and Development Organization, headquartered out of Hyderabad, India,…
Read More » - Health
CHMP issues positive opinion for Jardiance® (empagliflozin) for the treatment of adults with heart failure with reduced ejection fraction
Ingelheim, Germany: – The positive opinion is based on the EMPEROR-Reduced trial, which showed a significant 25 percent reduction in…
Read More » - Health
Yale-Boehringer Ingelheim Biomedical Data Science Fellowship Program Seeks to Attract Top Researchers from Around the World
Ingelheim, Germany & New Haven, Conn., United States: Yale University, in partnership with Boehringer Ingelheim, today announced the launch of…
Read More » - Business
Boehringer Ingelheim and Zealand Pharma Advance to Phase 2 Clinical Testing in NASH and Obesity
Copenhagen, Denmark & Ingelheim, Germany: New studies mark an important advancement of Boehringer Ingelheim’s cardiometabolic focus areas obesity and NASH.…
Read More » - Business Wire
Boehringer Ingelheim sees positive business momentum in 2020 despite impact of COVID-19
Strong R&D commitment to developing therapeutics against SARS-CoV-2 virus Overall R&D investment up 7% to 3.7 billion EUR in 2020…
Read More » - Technology
Quantum Computing: Boehringer Ingelheim and Google Partner for Pharma R&D
Ingelheim, Germany & Mountain View, Calif., United States: ● Quantum computing offers the potential to significantly accelerate and optimize the…
Read More » - Health
Boehringer Ingelheim to Acquire NBE-Therapeutics for EUR 1.18 Billion, Significantly Enhancing Its Cancer Pipeline Portfolio with Novel Antibody-Drug Conjugates
Ingelheim, Germany & Basel, Switzerland: Acquisition will add another key dimension to Boehringer Ingelheim’s focus on patients with difficult-to-treat solid…
Read More » - Health
Boehringer Ingelheim to Acquire Labor Dr. Merk & Kollegen to Strengthen its Next Generation Cancer Immunology Program
Ochsenhausen, Ingelheim am Rhein, Germany: Boehringer Ingelheim has signed the agreement on the acquisition of all shares of Germany-based biotech…
Read More » - World
Boehringer Ingelheim Collaborates with Proxygen to Explore Molecular Glue Degraders – a Novel Approach to Fight Cancer
Vienna, Austria & Ingelheim, Germany: – New collaboration strengthens Boehringer Ingelheim’s cancer research strategy to develop novel treatment options for…
Read More » - United States
Empagliflozin reduced the risk of first plus recurrent cardiovascular events in adults with type 2 diabetes and established cardiovascular disease in new analysis from the EMPA-REG OUTCOME® trial
Ingelheim, Germany & Indianapolis, United States: – In new results published in The Lancet Diabetes & Endocrinology, empagliflozin reduced the risk of total…
Read More » - Health
Boehringer Ingelheim receives positive CHMP opinion for use of Pradaxa® (dabigatran etexilate) for the treatment and prevention of venous thromboembolic events in children from birth to less than 18 years of age
Ingelheim, Germany: No approved therapy for the treatment and prevention of venous thromboembolic events in children until now Current standard…
Read More » - Health
New Analysis Supports Long-Term Treatment with nintedanib in SSc-ILD Patients1
Ingelheim, Germany: Interim analysis demonstrated long-term safety and suggested a sustained effect of nintedanib on slowing lung function decline in…
Read More » - Health
Boehringer Ingelheim Begins Phase 2 Clinical Trial of a Targeted Therapy to Help People with Severe Respiratory Illness from COVID-19
Ingelheim, Germany: Trial will evaluate BI 764198, a novel first-in-class compound, for hospitalized people infected with SARS-CoV-2 with severe respiratory…
Read More » -
Veeva Teams With Life Sciences to Offer Industrywide Source for Key Contacts, Information, and Services From Across Companies and Brands
Sydney, Australia: MyVeeva for Doctors app makes it easy for HCPs to access the people and resources they need to…
Read More » - Health
Boehringer Ingelheim and Oxford BioTherapeutics Expand Collaboration to Discover Novel Selective Tumor Targets as First Bispecific Antibody Advanced into the Clinic
Oxford, England & Ingelheim, Germany: The collaboration for the discovery of novel selective tumor targets for Boehringer Ingelheim’s unique T-cell…
Read More » - World
Phase II trial results demonstrated improvement in cognition with BI 425809 in adult patients with schizophrenia
Ingelheim, Germany: Results presented at the 33rd ECNP Congress from a 12-week, placebo-controlled Phase II trial demonstrated BI 425809 has…
Read More » - Business
Boehringer Ingelheim and Click Therapeutics Enter into Collaboration to Develop and Commercialize CT-155, a Novel Prescription Digital Therapeutic to Aid in the Treatment of Schizophrenia
Ingelheim, Germany: This collaboration combines Click Therapeutics’ specialty in developing efficacious and engaging digital therapeutics with Boehringer Ingelheim’s expertise in…
Read More » - Health
Boehringer Ingelheim Advances Novel Bi-specific TRAILR2/CDH17 Antibody to Phase 1 Clinical Trial for Patients Living with Gastrointestinal Cancers
Ingelheim, Germany: First-in-class bi-specific antibody BI 905711 activates a pathway in TRAILR2 and CDH17 co-expressing tumor cells that leads to…
Read More » - Health
Empagliflozin reduced the combined relative risk of cardiovascular death and hospitalization for heart failure by 25 percent in adults with and without diabetes who had heart failure with reduced ejection fraction
Ingelheim, Germany & Indianapolis, United States: Empagliflozin also significantly reduced the relative risk of first and recurrent hospitalization for heart…
Read More »